dsDNA Viruses

CCHEMISTRY METALLURGY C12Biochemistry C12NMICRO-ORGANISMS OR ENZYMES COMPOSITIONS THEREOF PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS MUTATION OR GENETIC ENGINEERING CULTURE MEDIA

C12N2710/00dsDNA Viruses

C12N2710/00011dsDNA Viruses C12N2710/00021Viruses as such C12N2710/00022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/00023Virus like particles [VLP] C12N2710/00031Uses of virus other than therapeutic or vaccine C12N2710/00032Use of virus as therapeutic agent, other than vaccine C12N2710/00033Use of viral protein as therapeutic agent other than vaccine C12N2710/00034Use of virus or viral component as vaccine C12N2710/00041Use of virus, viral particle or viral elements as a vector C12N2710/00042virus or viral particle as vehicle C12N2710/00043viral genome or elements thereof as genetic vector C12N2710/00044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/00045Special targeting system for viral vectors C12N2710/00051Methods of production or purification of viral material C12N2710/00052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/00061Methods of inactivation or attenuation C12N2710/00062by genetic engineering C12N2710/00063by chemical treatment C12N2710/00064by serial passage C12N2710/00071Demonstrated in vivo effect C12N2710/00088For redistribution C12N2710/10011Adenoviridae C12N2710/10021Viruses as such C12N2710/10022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/10023Virus like particles [VLP] C12N2710/10031Uses of virus other than therapeutic or vaccine C12N2710/10032Use of virus as therapeutic agent, other than vaccine C12N2710/10033Use of viral protein as therapeutic agent other than vaccine C12N2710/10034Use of virus or viral component as vaccine C12N2710/10041Use of virus, viral particle or viral elements as a vector C12N2710/10042virus or viral particle as vehicle C12N2710/10043viral genome or elements thereof as genetic vector C12N2710/10044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/10045Special targeting system for viral vectors C12N2710/10051Methods of production or purification of viral material C12N2710/10052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/10061Methods of inactivation or attenuation C12N2710/10062by genetic engineering C12N2710/10063by chemical treatment C12N2710/10064by serial passage C12N2710/10071Demonstrated in vivo effect C12N2710/10088For redistribution C12N2710/10111Atadenovirus C12N2710/10121Viruses as such C12N2710/10122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/10123Virus like particles [VLP] C12N2710/10131Uses of virus other than therapeutic or vaccine C12N2710/10132Use of virus as therapeutic agent, other than vaccine C12N2710/10133Use of viral protein as therapeutic agent other than vaccine C12N2710/10134Use of virus or viral component as vaccine C12N2710/10141Use of virus, viral particle or viral elements as a vector C12N2710/10142virus or viral particle as vehicle C12N2710/10143viral genome or elements thereof as genetic vector C12N2710/10144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/10145Special targeting system for viral vectors C12N2710/10151Methods of production or purification of viral material C12N2710/10152relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/10161Methods of inactivation or attenuation C12N2710/10162by genetic engineering C12N2710/10163by chemical treatment C12N2710/10164by serial passage C12N2710/10171Demonstrated in vivo effect C12N2710/10188For redistribution C12N2710/10211Aviadenovirus C12N2710/10221Viruses as such C12N2710/10222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/10223Virus like particles [VLP] C12N2710/10231Uses of virus other than therapeutic or vaccine C12N2710/10232Use of virus as therapeutic agent, other than vaccine C12N2710/10233Use of viral protein as therapeutic agent other than vaccine C12N2710/10234Use of virus or viral component as vaccine C12N2710/10241Use of virus, viral particle or viral elements as a vector C12N2710/10242virus or viral particle as vehicle C12N2710/10243viral genome or elements thereof as genetic vector C12N2710/10244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/10245Special targeting system for viral vectors C12N2710/10251Methods of production or purification of viral material C12N2710/10252relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/10261Methods of inactivation or attenuation C12N2710/10262by genetic engineering C12N2710/10263by chemical treatment C12N2710/10264by serial passage C12N2710/10271Demonstrated in vivo effect C12N2710/10288For redistribution C12N2710/10311Mastadenovirus C12N2710/10321Viruses as such C12N2710/10322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/10323Virus like particles [VLP] C12N2710/10331Uses of virus other than therapeutic or vaccine C12N2710/10332Use of virus as therapeutic agent, other than vaccine C12N2710/10333Use of viral protein as therapeutic agent other than vaccine C12N2710/10334Use of virus or viral component as vaccine C12N2710/10341Use of virus, viral particle or viral elements as a vector C12N2710/10342virus or viral particle as vehicle C12N2710/10343viral genome or elements thereof as genetic vector C12N2710/10344Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/10345Special targeting system for viral vectors C12N2710/10351Methods of production or purification of viral material C12N2710/10352relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/10361Methods of inactivation or attenuation C12N2710/10362by genetic engineering C12N2710/10363by chemical treatment C12N2710/10364by serial passage C12N2710/10371Demonstrated in vivo effect C12N2710/10388For redistribution C12N2710/12011Asfarviridae C12N2710/12021Viruses as such C12N2710/12022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/12023Virus like particles [VLP] C12N2710/12031Uses of virus other than therapeutic or vaccine C12N2710/12032Use of virus as therapeutic agent, other than vaccine C12N2710/12033Use of viral protein as therapeutic agent other than vaccine C12N2710/12034Use of virus or viral component as vaccine C12N2710/12041Use of virus, viral particle or viral elements as a vector C12N2710/12042virus or viral particle as vehicle C12N2710/12043viral genome or elements thereof as genetic vector C12N2710/12044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/12045Special targeting system for viral vectors C12N2710/12051Methods of production or purification of viral material C12N2710/12052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/12061Methods of inactivation or attenuation C12N2710/12062by genetic engineering C12N2710/12063by chemical treatment C12N2710/12064by serial passage C12N2710/12071Demonstrated in vivo effect C12N2710/12088For redistribution C12N2710/14011Baculoviridae C12N2710/14021Viruses as such C12N2710/14022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/14023Virus like particles [VLP] C12N2710/14031Uses of virus other than therapeutic or vaccine C12N2710/14032Use of virus as therapeutic agent, other than vaccine C12N2710/14033Use of viral protein as therapeutic agent other than vaccine C12N2710/14034Use of virus or viral component as vaccine C12N2710/14041Use of virus, viral particle or viral elements as a vector C12N2710/14042virus or viral particle as vehicle C12N2710/14043viral genome or elements thereof as genetic vectore C12N2710/14044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/14045Special targeting system for viral vectors C12N2710/14051Methods of production or purification of viral material C12N2710/14052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/14061Methods of inactivation or attenuation C12N2710/14062by genetic engineering C12N2710/14063by chemical treatment C12N2710/14064by serial passage C12N2710/14071Demonstrated in vivo effect C12N2710/14088For redistribution C12N2710/14111Nucleopolyhedrovirus C12N2710/14121Viruses as such C12N2710/14122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/14123Virus like particles [VLP] C12N2710/14131Uses of virus other than therapeutic or vaccine C12N2710/14132Use of virus as therapeutic agent, other than vaccine C12N2710/14133Use of viral protein as therapeutic agent other than vaccine C12N2710/14134Use of virus or viral component as vaccine C12N2710/14141Use of virus, viral particle or viral elements as a vector C12N2710/14142virus or viral particle as vehicle C12N2710/14143viral genome or elements thereof as genetic vector C12N2710/14144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/14145Special targeting system for viral vectors C12N2710/14151Methods of production or purification of viral material C12N2710/14152relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/14161Methods of inactivation or attenuation C12N2710/14162by genetic engineering C12N2710/14163by chemical treatment C12N2710/14164by serial passage C12N2710/14171Demonstrated in vivo effect C12N2710/14188For redistribution C12N2710/16011Herpesviridae C12N2710/16021Viruses as such C12N2710/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16023Virus like particles [VLP] C12N2710/16031Uses of virus other than therapeutic or vaccine C12N2710/16032Use of virus as therapeutic agent, other than vaccine C12N2710/16033Use of viral protein as therapeutic agent other than vaccine C12N2710/16034Use of virus or viral component as vaccine C12N2710/16041Use of virus, viral particle or viral elements as a vector C12N2710/16042virus or viral particle as vehicle C12N2710/16043viral genome or elements thereof as genetic vector C12N2710/16044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16045Special targeting system for viral vectors C12N2710/16051Methods of production or purification of viral material C12N2710/16052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/16061Methods of inactivation or attenuation C12N2710/16062by genetic engineering C12N2710/16063by chemical treatment C12N2710/16064by serial passage C12N2710/16071Demonstrated in vivo effect C12N2710/16088For redistribution C12N2710/16111Cytomegalovirus C12N2710/16121Viruses as such C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16123Virus like particles [VLP] C12N2710/16131Uses of virus other than therapeutic or vaccine C12N2710/16132Use of virus as therapeutic agent, other than vaccine C12N2710/16133Use of viral protein as therapeutic agent other than vaccine C12N2710/16134Use of virus or viral component as vaccine C12N2710/16141Use of virus, viral particle or viral elements as a vector C12N2710/16142virus or viral particle as vehicle C12N2710/16143viral genome or elements thereof as genetic vector C12N2710/16144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16145Special targeting system for viral vectors C12N2710/16151Methods of production or purification of viral material C12N2710/16152relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/16161Methods of inactivation or attenuation C12N2710/16162by genetic engineering C12N2710/16163by chemical treatment C12N2710/16164by serial passage C12N2710/16171Demonstrated in vivo effect C12N2710/16188For redistribution C12N2710/16211Lymphocryptovirus C12N2710/16221Viruses as such C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16223Virus like particles [VLP] C12N2710/16231Uses of virus other than therapeutic or vaccine C12N2710/16232Use of virus as therapeutic agent, other than vaccine C12N2710/16233Use of viral protein as therapeutic agent other than vaccine C12N2710/16234Use of virus or viral component as vaccine C12N2710/16241Use of virus, viral particle or viral elements as a vector C12N2710/16242virus or viral particle as vehicle C12N2710/16243viral genome or elements thereof as genetic vector C12N2710/16244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16245Special targeting system for viral vectors C12N2710/16251Methods of production or purification of viral material C12N2710/16252relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/16261Methods of inactivation or attenuation C12N2710/16262by genetic engineering C12N2710/16263by chemical treatment C12N2710/16264by serial passage C12N2710/16271Demonstrated in vivo effect C12N2710/16288For redistribution C12N2710/16311Mardivirus C12N2710/16321Viruses as such C12N2710/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16323Virus like particles [VLP] C12N2710/16331Uses of virus other than therapeutic or vaccine C12N2710/16332Use of virus as therapeutic agent, other than vaccine C12N2710/16333Use of viral protein as therapeutic agent other than vaccine C12N2710/16334Use of virus or viral component as vaccine C12N2710/16341Use of virus, viral particle or viral elements as a vector C12N2710/16342virus or viral particle as vehicle C12N2710/16343viral genome or elements thereof as genetic vector C12N2710/16344Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16345Special targeting system for viral vectors C12N2710/16351Methods of production or purification of viral material C12N2710/16352relating to complementin g cells and packaging systems for producing virus or viral particles C12N2710/16361Methods of inactivation or attenuation C12N2710/16362by genetic engineering C12N2710/16363by chemical treatment C12N2710/16364by serial passage C12N2710/16371Demonstrated in vivo effect C12N2710/16388For redistribution C12N2710/16411Rhadinovirus C12N2710/16421Viruses as such C12N2710/16422New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16423Virus like particles [VLP] C12N2710/16431Uses of virus other than therapeutic or vaccine C12N2710/16432Use of virus as therapeutic agent, other than vaccine C12N2710/16433Use of viral protein as therapeutic agent other than vaccine C12N2710/16434Use of virus or viral component as vaccine C12N2710/16441Use of virus, viral particle or viral elements as a vector C12N2710/16442virus or viral particle as vehicle C12N2710/16443viral genome or elements thereof as genetic vector C12N2710/16444Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16445Special targeting system for viral vectors C12N2710/16451Methods of production or purification of viral material C12N2710/16452relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/16461Methods of inactivation or attenuation C12N2710/16462by genetic engineering C12N2710/16463by chemical treatment C12N2710/16464by serial passage C12N2710/16471Demonstrated in vivo effect C12N2710/16488For redistribution C12N2710/16511Roseolovirus C12N2710/16521Viruses as such C12N2710/16522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16523Virus like particles [VLP] C12N2710/16531Uses of virus other than therapeutic or vaccine C12N2710/16532Use of virus as therapeutic agent, other than vaccine C12N2710/16533Use of viral protein as therapeutic agent other than vaccine C12N2710/16534Use of virus or viral component as vaccine C12N2710/16541Use of virus, viral particle or viral elements as a vector C12N2710/16542virus or viral particle as vehicle C12N2710/16543viral genome or elements thereof as genetic vector C12N2710/16544Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16545Special targeting system for viral vectors C12N2710/16551Methods of production or purification of viral material C12N2710/16552relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/16561Methods of inactivation or attenuation C12N2710/16562by genetic engineering C12N2710/16563by chemical treatment C12N2710/16564by serial passage C12N2710/16571Demonstrated in vivo effect C12N2710/16588For redistribution C12N2710/16611Simplexvirus C12N2710/16621Viruses as such C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16623Virus like particles [VLP] C12N2710/16631Uses of virus other than therapeutic or vaccine C12N2710/16632Use of virus as therapeutic agent, other than vaccine C12N2710/16633Use of viral protein as therapeutic agent other than vaccine C12N2710/16634Use of virus or viral component as vaccine C12N2710/16641Use of virus, viral particle or viral elements as a vector C12N2710/16642virus or viral particle as vehicle C12N2710/16643viral genome or elements thereof as genetic vector C12N2710/16644Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16645Special targeting system for viral vectors C12N2710/16651Methods of production or purification of viral material C12N2710/16652relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/16661Methods of inactivation or attenuation C12N2710/16662by genetic engineering C12N2710/16663by chemical treatment C12N2710/16664by serial passage C12N2710/16671Demonstrated in vivo effect C12N2710/16688For redistribution C12N2710/16711Varicellovirus C12N2710/16721Viruses as such C12N2710/16722New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/16723Virus like particles [VLP] C12N2710/16731Uses of virus other than therapeutic or vaccine C12N2710/16732Use of virus as therapeutic agent, other than vaccine C12N2710/16733Use of viral protein as therapeutic agent other than vaccine C12N2710/16734Use of virus or viral component as vaccine C12N2710/16741Use of virus, viral particle or viral elements as a vector C12N2710/16742virus or viral particle as vehicle C12N2710/16743viral genome or elements thereof as genetic vector C12N2710/16744Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/16745Special targeting system for viral vectors C12N2710/16751Methods of production or purification of viral material C12N2710/16752relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/16761Methods of inactivation or attenuation C12N2710/16762by genetic engineering C12N2710/16763by chemical treatment C12N2710/16764by serial passage C12N2710/16771Demonstrated in vivo effect C12N2710/16788For redistribution C12N2710/18011Nimaviridae C12N2710/18021Viruses as such C12N2710/18022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/18023Virus like particles [VLP] C12N2710/18031Uses of virus other than therapeutic or vaccine C12N2710/18032Use of virus as therapeutic agent, other than vaccine C12N2710/18033Use of viral protein as therapeutic agent other than vaccine C12N2710/18034Use of virus or viral component as vaccine C12N2710/18041Use of virus, viral particle or viral elements as a vector C12N2710/18042virus or viral particle as vehicle C12N2710/18043viral genome or elements thereof as genetic vector C12N2710/18044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/18045Special targeting system for viral vectors C12N2710/18051Methods of production or purification of viral material C12N2710/18052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/18061Methods of inactivation or attenuation C12N2710/18062by genetic engineering C12N2710/18063by chemical treatment C12N2710/18064by serial passage C12N2710/18071Demonstrated in vivo effect C12N2710/18088For redistribution C12N2710/20011Papillomaviridae C12N2710/20021Viruses as such C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/20023Virus like particles [VLP] C12N2710/20031Uses of virus other than therapeutic or vaccine C12N2710/20032Use of virus as therapeutic agent, other than vaccine C12N2710/20033Use of viral protein as therapeutic agent other than vaccine C12N2710/20034Use of virus or viral component as vaccine C12N2710/20041Use of virus, viral particle or viral elements as a vector C12N2710/20042virus or viral particle as vehicle C12N2710/20043viral genome or elements thereof as genetic vector C12N2710/20044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/20045Special targeting system for viral vectors C12N2710/20051Methods of production or purification of viral material C12N2710/20052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/20061Methods of inactivation or attenuation C12N2710/20062by genetic engineering C12N2710/20063by chemical treatment C12N2710/20064by serial passage C12N2710/20071Demonstrated in vivo effect C12N2710/20088For redistribution C12N2710/22011Polyomaviridae C12N2710/22021Viruses as such C12N2710/22022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/22023Virus like particles [VLP] C12N2710/22031Uses of virus other than therapeutic or vaccine C12N2710/22032Use of virus as therapeutic agent, other than vaccine C12N2710/22033Use of viral protein as therapeutic agent other than vaccine C12N2710/22034Use of virus or viral component as vaccine C12N2710/22041Use of virus, viral particle or viral elements as a vector C12N2710/22042virus or viral particle as vehicle C12N2710/22043viral genome or elements thereof as genetic vector C12N2710/22044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/22045Special targeting system for viral vectors C12N2710/22051Methods of production or purification of viral material C12N2710/22052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/22061Methods of inactivation or attenuation C12N2710/22062by genetic engineering C12N2710/22063by chemical treatment C12N2710/22064by serial passage C12N2710/22071Demonstrated in vivo effect C12N2710/22088For redistribution C12N2710/24011Poxviridae C12N2710/24021Viruses as such C12N2710/24022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/24023Virus like particles [VLP] C12N2710/24031Uses of virus other than therapeutic or vaccine C12N2710/24032Use of virus as therapeutic agent, other than vaccine C12N2710/24033Use of viral protein as therapeutic agent other than vaccine C12N2710/24034Use of virus or viral component as vaccine C12N2710/24041Use of virus, viral particle or viral elements as a vector C12N2710/24042virus or viral particle as vehicle C12N2710/24043viral genome or elements thereof as genetic vector C12N2710/24044Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/24045Special targeting system for viral vectors C12N2710/24051Methods of production or purification of viral material C12N2710/24052relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/24061Methods of inactivation or attenuation C12N2710/24062by genetic engineering C12N2710/24063by chemical treatment C12N2710/24064by serial passage C12N2710/24071Demonstrated in vivo effect C12N2710/24088For redistribution C12N2710/24111Orthopoxvirus C12N2710/24121Viruses as such C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/24123Virus like particles [VLP] C12N2710/24131Uses of virus other than therapeutic or vaccine C12N2710/24132Use of virus as therapeutic agent, other than vaccine C12N2710/24133Use of viral protein as therapeutic agent other than vaccine C12N2710/24134Use of virus or viral component as vaccine C12N2710/24141Use of virus, viral particle or viral elements as a vector C12N2710/24142virus or viral particle as vehicle C12N2710/24143viral genome or elements thereof as genetic vector C12N2710/24144Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/24145Special targeting system for viral vectors C12N2710/24151Methods of production or purification of viral material C12N2710/24152relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/24161Methods of inactivation or attenuation C12N2710/24162by genetic engineering C12N2710/24163by chemical treatment C12N2710/24164by serial passage C12N2710/24171Demonstrated in vivo effect C12N2710/24188For redistribution C12N2710/24211Parapoxvirus C12N2710/24221Viruses as such C12N2710/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes C12N2710/24223Virus like particles [VLP] C12N2710/24231Uses of virus other than therapeutic or vaccine C12N2710/24232Use of virus as therapeutic agent, other than vaccine C12N2710/24233Use of viral protein as therapeutic agent other than vaccine C12N2710/24234Use of virus or viral component as vaccine C12N2710/24241Use of virus, viral particle or viral elements as a vector C12N2710/24242virus or viral particle as vehicle C12N2710/24243viral genome or elements thereof as genetic vector C12N2710/24244Chimeric viral vector comprising heterologous viral elements for production of another viral vector C12N2710/24245Special targeting system for viral vectors C12N2710/24251Methods of production or purification of viral material C12N2710/24252relating to complementing cells and packaging systems for producing virus or viral particles C12N2710/24261Methods of inactivation or attenuation C12N2710/24262by genetic engineering C12N2710/24263by chemical treatment C12N2710/24264by serial passage C12N2710/24271Demonstrated in vivo effect C12N2710/24288For redistribution